Cardiovascular risk not increased with mirabegron.

Findings were similar when restricted to patients at high CV risk, in younger versus older adults (<65 years vs >=65 years) and based on prior OAB medication. The risk of adverse cardiovascular (CV) events in patients with overactive bladder (OAB) does not appear to be increased with mirabegron compared with muscarinic antagonists, according to findings of the Astellas Pharma-funded Mirabegron PMR-PASS [1] study published in I Drug Safety i . Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study Drug Safety: 8 Jul 2021. [Extracted from the article]